24 results on '"Loughran, Jr., Thomas P."'
Search Results
2. Acid Ceramidase Inhibitor LCL-805 Antagonizes Akt Signaling and Promotes Iron-Dependent Cell Death in Acute Myeloid Leukemia.
- Author
-
Ung, Johnson, Tan, Su-Fern, Fox, Todd E., Shaw, Jeremy J. P., Taori, Maansi, Horton, Bethany J., Golla, Upendarrao, Sharma, Arati, Szulc, Zdzislaw M., Wang, Hong-Gang, Chalfant, Charles E., Cabot, Myles C., Claxton, David F., Loughran Jr., Thomas P., and Feith, David J.
- Subjects
THERAPEUTIC use of antineoplastic agents ,IN vitro studies ,CHELATION therapy ,IRON ,ACID ceramidase ,APOPTOSIS ,IRON in the body ,CELL survival ,TREATMENT effectiveness ,TRANSFERASES ,DESCRIPTIVE statistics ,CELL lines ,SPHINGOLIPIDS ,CHEMICAL inhibitors - Abstract
Simple Summary: The lysosomal lipid hydrolase acid ceramidase is upregulated in acute myeloid leukemia and promotes leukemic blast survival, underscoring its potential for therapeutic targeting. B-13 is an established ceramidase inhibitor with demonstrated efficacy in multiple solid cancers. Next-generation lysosome-localizing prodrugs of B-13 have been developed but have not been evaluated in AML. This study characterizes the in vitro anti-leukemic efficacy and cell death mechanisms of the B-13 analog and acid ceramidase inhibitor LCL-805 in acute myeloid leukemia. Acute myeloid leukemia (AML) is an aggressive hematologic malignancy requiring urgent treatment advancements. Ceramide is a cell-death-promoting signaling lipid that plays a central role in therapy-induced cell death. We previously determined that acid ceramidase (AC), a ceramide-depleting enzyme, is overexpressed in AML and promotes leukemic survival and drug resistance. The ceramidase inhibitor B-13 and next-generation lysosomal-localizing derivatives termed dimethylglycine (DMG)-B-13 prodrugs have been developed but remain untested in AML. Here, we report the in vitro anti-leukemic efficacy and mechanism of DMG-B-13 prodrug LCL-805 across AML cell lines and primary patient samples. LCL-805 inhibited AC enzymatic activity, increased total ceramides, and reduced sphingosine levels. A median EC50 value of 11.7 μM was achieved for LCL-805 in cell viability assays across 32 human AML cell lines. As a single agent tested across a panel of 71 primary AML patient samples, a median EC50 value of 15.8 μM was achieved. Exogenous ceramide supplementation with C6-ceramide nanoliposomes, which is entering phase I/II clinical trial for relapsed/refractory AML, significantly enhanced LCL-805 killing. Mechanistically, LCL-805 antagonized Akt signaling and led to iron-dependent cell death distinct from canonical ferroptosis. These findings elucidated key factors involved in LCL-805 cytotoxicity and demonstrated the potency of combining AC inhibition with exogenous ceramide. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Retrovirus insertion site analysis of LGL leukemia patient genomes
- Author
-
Li, Weiling, Yang, Lei, Harris, Robert S., Lin, Lin, Olson, Thomas L., Hamele, Cait E., Feith, David J., Loughran, Jr, Thomas P., and Poss, Mary
- Published
- 2019
- Full Text
- View/download PDF
4. Simultaneous Inhibition of Ceramide Hydrolysis and Glycosylation Synergizes to Corrupt Mitochondrial Respiration and Signal Caspase Driven Cell Death in Drug-Resistant Acute Myeloid Leukemia.
- Author
-
Fisher-Wellman, Kelsey H., Kassai, Miki, Hagen, James T., Neufer, P. Darrell, Kester, Mark, Loughran Jr., Thomas P., Chalfant, Charles E., Feith, David J., Tan, Su-Fern, Fox, Todd E., Ung, Johnson, Fabrias, Gemma, Abad, Jose' Luis, Sharma, Arati, Golla, Upendarrao, Claxton, David F., Shaw, Jeremy J. P., Bhowmick, Debajit, and Cabot, Myles C.
- Subjects
THERAPEUTIC use of antineoplastic agents ,PHYSICAL & theoretical chemistry ,ANIMAL experimentation ,PSYCHOLOGICAL vulnerability ,CERAMIDES ,MITOCHONDRIA ,TREATMENT effectiveness ,COMPARATIVE studies ,TRANSFERASES ,DESCRIPTIVE statistics ,RESEARCH funding ,RESPIRATION ,CASPASES ,DRUG resistance in cancer cells ,CELL death ,MICE ,PHENOTYPES - Abstract
Simple Summary: The sphingolipid ceramide is a key player in cytotoxic responses elicited by many anticancer drugs. Confounding this asset, however, are enzymes that promote ceramide clearance, thus limiting the propagation of ceramide-driven cancer cell death. Because several key ceramide-metabolizing enzymes have been shown to be upregulated in chemotherapy-resistant acute myeloid leukemia (AML) cells compared to chemotherapy-naïve counterparts, the current study was designed to determine the effects of blocking ceramide clearance in drug-resistant AML. For this, we employed simultaneous inhibition of ceramide hydrolysis and ceramide glycosylation and demonstrated that this dual blockade produced multi-fold elevations in intracellular ceramide levels, corrupted mitochondrial function, enhanced caspase activation, and elicited cell death in models of drug-resistant AML. We have herein identified sphingolipid metabolic junctures that can be targeted to enhance leukemia cell vulnerability in the drug-resistant setting, thus providing a novel therapeutic modality in difficult-to-treat cancers. Acute myelogenous leukemia (AML), the most prevalent acute and aggressive leukemia diagnosed in adults, often recurs as a difficult-to-treat, chemotherapy-resistant disease. Because chemotherapy resistance is a major obstacle to successful treatment, novel therapeutic intervention is needed. Upregulated ceramide clearance via accelerated hydrolysis and glycosylation has been shown to be an element in chemotherapy-resistant AML, a problem considering the crucial role ceramide plays in eliciting apoptosis. Herein we employed agents that block ceramide clearance to determine if such a "reset" would be of therapeutic benefit. SACLAC was utilized to limit ceramide hydrolysis, and D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-threo-PDMP) was used to block the glycosylation route. The SACLAC D-threo-PDMP inhibitor combination was synergistically cytotoxic in drug-resistant, P-glycoprotein-expressing (P-gp) AML but not in wt, P-gp-poor cells. Interestingly, P-gp antagonists that can limit ceramide glycosylation via depression of glucosylceramide transit also synergized with SACLAC, suggesting a paradoxical role for P-gp in the implementation of cell death. Mechanistically, cell death was accompanied by a complete drop in ceramide glycosylation, concomitant, striking increases in all molecular species of ceramide, diminished sphingosine 1-phosphate levels, resounding declines in mitochondrial respiratory kinetics, altered Akt, pGSK-3β, and Mcl-1 expression, and caspase activation. Although ceramide was generated in wt cells upon inhibitor exposure, mitochondrial respiration was not corrupted, suggestive of mitochondrial vulnerability in the drug-resistant phenotype, a potential therapeutic avenue. The inhibitor regimen showed efficacy in an in vivo model and in primary AML cells from patients. These results support the implementation of SL enzyme targeting to limit ceramide clearance as a therapeutic strategy in chemotherapy-resistant AML, inclusive of a novel indication for the use of P-gp antagonists. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human
- Author
-
Yu, Jianhua, Mitsui, Takeki, Wei, Min, Mao, Hsiaoyin, Butchar, Jonathan P., Shah, Mithun Vinod, Zhang, Jianying, Mishra, Anjali, Alvarez-Breckenridge, Christopher, Liu, Xingluo, Liu, Shujun, Yokohama, Akihiko, Trotta, Rossana, Marcucci, Guido, Benson, Jr., Don M., Loughran, Jr., Thomas P., Tridandapani, Susheela, and Caligiuri, Michael A.
- Subjects
T cells -- Health aspects ,Gene expression -- Research ,Leukemia -- Genetic aspects -- Care and treatment ,Health care industry - Abstract
IL-15 may have a role in the development of T cell large granular lymphocyte (T-LGL) or NKT leukemias. However, the mechanisms of action and the identity of the cell subset that undergoes leukemic transformation remain elusive. Here we show that in both mice and humans, NKp46 expression marks a minute population of WT NKT cells with higher activity and potency to become leukemic. Virtually 100% of T-LGL leukemias in IL-15 transgenic mice expressed NKp46, as did a majority of human T-LGL leukemias. The minute [NKp46.sup.+] NKT population, but not the NKp46 NKT population, was selectively expanded by overexpression of endogenous IL-15. Importantly, IL-15 transgenic NKp46 NKT cells did not become [NKp46.sup.+] in vivo, suggesting that [NKp46.sup.+] T-LGL leukemia cells were the malignant counterpart of the minute WT [NKp46.sup.+] NKT population. Mechanistically, [NKp46.sup.+] NKT cells possessed higher responsiveness to IL-15 in vitro and in vivo compared with that of their NKp46 NKT counterparts. Furthermore, interruption of IL-15 signaling using a neutralizing antibody could prevent LGL leukemia in IL-15 transgenic mice. Collectively, our data demonstrate that NKp46 identifies a functionally distinct NKT subset in mice and humans that appears to be directly susceptible to leukemic transformation when IL-15 is overexpressed. Thus, IL-15 signaling and NKp46 maybe useful targets in the treatment of patients with T-LGL or NKT leukemia., Introduction NKT cells are defined as a subset of T cells that share some characteristics with NK cells, particularly expression of the NK1.1 or DX5 antigen in mice and CD56 [...]
- Published
- 2011
- Full Text
- View/download PDF
6. Intersection Between Large Granular Lymphocyte Leukemia and Rheumatoid Arthritis.
- Author
-
Moosic, Katharine B., Ananth, Kusuma, Andrade, Felipe, Feith, David J., Darrah, Erika, and Loughran Jr, Thomas P.
- Subjects
RHEUMATOID arthritis ,LEUKEMIA ,LYMPHOCYTES ,CYTOTOXIC T cells ,HEMATOLOGIC malignancies ,THERAPEUTICS - Abstract
Large granular lymphocyte (LGL) leukemia, a rare hematologic malignancy, has long been associated with rheumatoid arthritis (RA), and the diseases share numerous common features. This review aims to outline the parallels and comparisons between the diseases as well as discuss the potential mechanisms for the relationship between LGL leukemia and RA. RA alone and in conjunction with LGL leukemia exhibits cytotoxic T-cell (CTL) expansions, HLA-DR4 enrichment, RA-associated autoantibodies, female bias, and unknown antigen specificity of associated T-cell expansions. Three possible mechanistic links between the pathogenesis of LGL leukemia and RA have been proposed, including LGL leukemia a) as a result of longstanding RA, b) as a consequence of RA treatment, or c) as a driver of RA. Several lines of evidence point towards LGL as a driver of RA. CTL involvement in RA pathogenesis is evidenced by citrullination and granzyme B cleavage that modifies the repertoire of self-protein antigens in target cells, particularly neutrophils, killed by the CTLs. Further investigations of the relationship between LGL leukemia and RA are warranted to better understand causal pathways and target antigens in order to improve the mechanistic understanding and to devise targeted therapeutic approaches for both disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL)
- Author
-
Epling-Burnette, Pearlie K, Bai, Fanqi, Wei, Sheng, Chaurasia, Pratima, Painter, Jeffrey S, Olashaw, Nancy, Hamilton, Andrew, Sebti, Said, Djeu, Julie Y, and Loughran, Jr, Thomas P
- Published
- 2004
- Full Text
- View/download PDF
8. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.
- Author
-
Dufva, Olli, Kankainen, Matti, Kelkka, Tiina, Sekiguchi, Nodoka, Awad, Shady Adnan, Eldfors, Samuli, Yadav, Bhagwan, Kuusanmäki, Heikki, Malani, Disha, Andersson, Emma I., Pietarinen, Paavo, Saikko, Leena, Kovanen, Panu E., Ojala, Teija, Lee, Dean A., Loughran Jr., Thomas P., Nakazawa, Hideyuki, Suzumiya, Junji, Suzuki, Ritsuro, and Young Hyeh Ko
- Abstract
Aggressive natural killer-cell (NK-cell) leukemia (ANKL) is an extremely aggressive malignancy with dismal prognosis and lack of targeted therapies. Here, we elucidate the molecular pathogenesis of ANKL using a combination of genomic and drug sensitivity profiling. We study 14 ANKL patients using whole-exome sequencing (WES) and identify mutations in STAT3 (21%) and RAS-MAPK pathway genes (21%) as well as in DDX3X (29%) and epigenetic modifiers (50%). Additional alterations include JAK-STAT copy gains and tyrosine phosphatase mutations, which we show recurrent also in extranodal NK/T-cell lymphoma, nasal type (NKTCL) through integration of public genomic data. Drug sensitivity profiling further demonstrates the role of the JAK-STAT pathway in the pathogenesis of NK-cell malignancies, identifying NK cells to be highly sensitive to JAK and BCL2 inhibition compared to other hematopoietic cell lineages. Our results provide insight into ANKL genetics and a framework for application of targeted therapies in NK-cell malignancies. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
9. Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression
- Author
-
Doi, Kenichiro, primary, Liu, Qiang, additional, Gowda, Krishne, additional, Barth, Brian M, additional, Claxton, David, additional, Amin, Shantu, additional, Loughran Jr, Thomas P, additional, and Wang, Hong-Gang, additional
- Published
- 2014
- Full Text
- View/download PDF
10. C6-Ceramide Nanoliposomes Target the Warburg Effect in Chronic Lymphocytic Leukemia
- Author
-
Ryland, Lindsay K., primary, Doshi, Ushma A., additional, Shanmugavelandy, Sriram S., additional, Fox, Todd E., additional, Aliaga, Cesar, additional, Broeg, Kathleen, additional, Baab, Kendall Thomas, additional, Young, Megan, additional, Khan, Osman, additional, Haakenson, Jeremy K., additional, Jarbadan, Nancy Ruth, additional, Liao, Jason, additional, Wang, Hong-Gang, additional, Feith, David J., additional, Loughran Jr, Thomas P., additional, Liu, Xin, additional, and Kester, Mark, additional
- Published
- 2013
- Full Text
- View/download PDF
11. Identification of indels in next-generation sequencing data.
- Author
-
Ratan, Aakrosh, Olson, Thomas L., Loughran Jr, Thomas P., and Miller, Webb
- Subjects
GENOMICS ,MOLECULAR genetics ,GENOMES ,SINGLE nucleotide polymorphisms ,BIOINFORMATICS - Abstract
Background: The discovery and mapping of genomic variants is an essential step in most analysis done using sequencing reads. There are a number of mature software packages and associated pipelines that can identify single nucleotide polymorphisms (SNPs) with a high degree of concordance. However, the same cannot be said for tools that are used to identify the other types of variants. Indels represent the second most frequent class of variants in the human genome, after single nucleotide polymorphisms. The reliable detection of indels is still a challenging problem, especially for variants that are longer than a few bases. Results: We have developed a set of algorithms and heuristics collectively called indelMINER to identify indels from whole genome resequencing datasets using paired-end reads. indelMINER uses a split-read approach to identify the precise breakpoints for indels of size less than a user specified threshold, and supplements that with a paired-end approach to identify larger variants that are frequently missed with the split-read approach. We use simulated and real datasets to show that an implementation of the algorithm performs favorably when compared to several existing tools. Conclusions: indelMINER can be used effectively to identify indels in whole-genome resequencing projects. The output is provided in the VCF format along with additional information about the variant, including information about its presence or absence in another sample. The source code and documentation for indelMINER can be freely downloaded from www.bx.psu.edu/miller_lab/indelMINER.tar.gz. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression.
- Author
-
Kenichiro Doi, Qiang Liu, Gowda, Krishne, Barth, Brian M., Claxton, David, Amin, Shantu, Loughran Jr, Thomas P., and Hong-Gang Wang
- Published
- 2014
- Full Text
- View/download PDF
13. DJ4 Targets the Rho-Associated Protein Kinase Pathway and Attenuates Disease Progression in Preclinical Murine Models of Acute Myeloid Leukemia.
- Author
-
Golla, Upendarrao, Ehudin, Melanie A., Annageldiyev, Charyguly, Zeng, Zheng, Bastihalli Tukaramrao, Diwakar, Tarren, Anna, Date, Abhijit A., Elcheva, Irina, Berg, Arthur, Amin, Shantu, Loughran Jr., Thomas P., Kester, Mark, Desai, Dhimant, Dovat, Sinisa, Claxton, David, and Sharma, Arati
- Subjects
PROTEIN kinases ,DISEASE progression ,BIOLOGICAL models ,RODENTS ,XENOGRAFTS ,PHOSPHOTRANSFERASES ,PROTEIN kinase inhibitors ,ANIMAL experimentation ,ACUTE myeloid leukemia ,DESCRIPTIVE statistics ,CELL lines ,PHARMACODYNAMICS - Abstract
Simple Summary: Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow with high relapse rates. Standard AML treatment has evolved to yield more frequent remission for patients, with little effect on the disease's low five-year survival rate. Patients exhibit a wide variation of molecular alterations, driving efforts to profile patients based on these genetic mutations. Previously, our group developed a novel Rho-associated protein kinase (ROCK) inhibitor, DJ4, and biochemical analysis demonstrated its potency in human cancer cell lines. This work targets the overactive ROCKs, which will help patients that experience abnormalities with ROCK-related processes that have been correlated to various cancers. We provide evidence to support the therapeutic efficacy of DJ4 and indicate its promise to improve AML therapy. Our results indicate that inhibiting ROCK makes AML cells susceptible to cell death and, in leukemia mouse models, reduces disease progression and enhances survival. The poor prognosis of acute myeloid leukemia (AML) and the highly heterogenous nature of the disease motivates targeted gene therapeutic investigations. Rho-associated protein kinases (ROCKs) are crucial for various actin cytoskeletal changes, which have established malignant consequences in various cancers, yet are still not being successfully utilized clinically towards cancer treatment. This work establishes the therapeutic activity of ROCK inhibitor (5Z)-2–5-(1H-pyrrolo[2,3-b]pyridine-3-ylmethylene)-1,3-thiazol-4(5H)-one (DJ4) in both in vitro and in vivo preclinical models of AML to highlight the potential of this class of inhibitors. Herein, DJ4 induced cytotoxic and proapoptotic effects in a dose-dependent manner in human AML cell lines (IC
50 : 0.05–1.68 μM) and primary patient cells (IC50 : 0.264–13.43 μM); however, normal hematopoietic cells were largely spared. ROCK inhibition by DJ4 disrupts the phosphorylation of downstream targets, myosin light chain (MLC2) and myosin-binding subunit of MLC phosphatase (MYPT), yielding a potent yet selective treatment response at micromolar concentrations, from 0.02 to 1 μM. Murine models injected with luciferase-expressing leukemia cell lines subcutaneously or intravenously and treated with DJ4 exhibited an increase in overall survival and reduction in disease progression relative to the vehicle-treated control mice. Overall, DJ4 is a promising candidate to utilize in future investigations to advance the current AML therapy. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
14. Network model of survival signaling in large granular lymphocyte leukemia.
- Author
-
Ranran Zhang, Shah, Mithun Vinod, Jun Yang, Nyland, Susan B., Xin Liu, Yun, Jong K., AIbert, Réka, and Loughran Jr., Thomas P.
- Subjects
T cells ,LYMPHOCYTES ,LEUKEMIA ,ANTIGENS ,CANCER ,TUMORS ,VACCINES - Abstract
T cell large granular lymphocyte (T-LGL) leukemia features a clonal expansion of antigen-primed, competent, cytotoxic T lymphocytes (CTL). To systematically understand signaling components that determine the survival of CTL in T-LGL leukemia, we constructed a T-LGL survival signaling network by integrating the signaling pathways involved in normal CTL activation and the known deregulations of survival signaling in leukemic T-LGL. This network was subsequently translated into a predictive, discrete, dynamic model. Our model suggests that the persistence of IL-15 and PDGF is sufficient to reproduce all known deregulations in leukemic T-LGL. This finding leads to the following predictions: (`) Inhibiting PDGF signaling induces apoptosis in leukemic T-LGL. (ii) Sphingosine kinase 1 and NFκB are essential for the long-term survival of CTL in T-LGL leukemia. (iii) NFκB functions downstream of PI3K and prevents apoptosis through maintaining the expression of myeloid cell leukemia sequence 1. (iv) T box expressed in T cells (T-bet) should be constitutively activated concurrently with NFκB activation to reproduce the leukemic T-LGL phenotype. We validated these predictions experimentally. Our study provides a model describing the signaling network involved in maintaining the long-term survival of competent CTL in humans. The model will be useful in identifying potential therapeutic targets for T-LGL leukemia and generating long-term competent CTL necessary for tumor and cancer vaccine development. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
15. Microarray results: how accurate are they?
- Author
-
Kothapalli, Ravi, Yoder, Sean J., Mane, Shrikant, and Loughran Jr., Thomas P.
- Subjects
DNA microarrays ,BIOCHIPS ,OLIGONUCLEOTIDES ,GENE expression ,GENES - Abstract
Background: DNA microarray technology is a powerful technique that was recently developed in order to analyze thousands of genes in a short time. Presently, microarrays, or chips, of the cDNA type and oligonucleotide type are available from several sources. The number of publications in this area is increasing exponentially. Results: In this study, microarray data obtained from two different commercially available systems were critically evaluated. Our analysis revealed several inconsistencies in the data obtained from the two different microarrays. Problems encountered included inconsistent sequence fidelity of the spotted microarrays, variability of differential expression, low specificity of cDNA microarray probes, discrepancy in fold-change calculation and lack of probe specificity for different isoforms of a gene. Conclusions: In view of these pitfalls, data from microarray analysis need to be interpreted cautiously. [ABSTRACT FROM AUTHOR]
- Published
- 2002
16. Multiple myeloma presenting as CEA-producing rectal cancer.
- Author
-
Talamo, Giampaolo, Barochia, Amitkumar, Zangari, Maurizio, and Loughran Jr., Thomas P.
- Subjects
MULTIPLE myeloma ,RECTAL cancer ,CARCINOEMBRYONIC antigen ,ADENOCARCINOMA - Abstract
We report the case of a 57-year-old patient with multiple myeloma, characterized by extramedullary involvement of the rectum at presentation. Malignant plasma cells were found to produce carcinoembryonic antigen (CEA), a tumor antigen more commonly associated with rectal adenocarcinomas. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
17. TRAIL mediates and sustains constitutive NF-kB activation in LGL leukemia.
- Author
-
Jun Yang, LeBlanc, Francis R., Dighe, Shubha A., Hamele, Cait E., Olson, Thomas L., Feith, David J., and Loughran Jr, Thomas P.
- Subjects
- *
LEUKEMIA , *APOPTOSIS , *T cells , *ANEMIA , *CELL death - Abstract
Large granular lymphocyte (LGL) leukemia results from clonal expansion of CD31 cytotoxic T lymphocytes or CD32 natural killer (NK) cells. Chronic antigen stimulation is postulated to promote long-term survival of LGL leukemia cells through constitutive activation of multiple survival pathways, resulting in global dysregulation of apoptosis and resistance to activation-induced cell death. We reported previously that nuclear factor kB (NF-kB) is a central regulator of the survival network for leukemic LGL. However, the mechanisms that trigger constitutive activation of NF-kB in LGL leukemia remain undefined. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is known to induce apoptosis in tumor cells but can also activate NF-kB through interaction with TRAIL receptors 1, 2, and 4 (also known as DR4, DR5, and DcR2, respectively). The role of TRAIL has not been studied in LGL leukemia. In this study, we hypothesized that TRAIL interaction with DcR2 contributes to NF-kB activation in LGL leukemia. We observed upregulated TRAIL messenger RNA and protein expression in LGL leukemia cells with elevated levels of soluble TRAIL protein in LGL leukemia patient sera. We also found that DcR2 is the predominant TRAIL receptor in LGL leukemia cells. We demonstrated that TRAIL-induced activation of DcR2 led to increased NF-kB activation in leukemic LGL. Conversely, interruption of TRAIL-DcR2 signaling led to decreased NF-kB activation. Finally, a potential therapeutic application of proteasome inhibitors (bortezomib and ixazomib), which are known to inhibit NF-kB, was identified through their ability to decrease proliferation and increase apoptosis in LGL leukemia cell lines and primary patient cells. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
18. Network Modeling of TGFβ Signaling in Hepatocellular Carcinoma Epithelial-to-Mesenchymal Transition Reveals Joint Sonic Hedgehog and Wnt Pathway Activation.
- Author
-
Steinway, Steven Nathaniel, Zañudo, Jorge G. T., Wei Ding, Rountree, Carl Bart, Feith, David J., Loughran Jr, Thomas P., and Albert, Reka
- Subjects
- *
TRANSFORMING growth factors-beta , *TRANSFORMING growth factors , *LIVER cancer , *CANCER cells , *METASTASIS - Abstract
Epithelial-to-mesenchymal transition (EMT) is a developmental process hijacked by cancer cells to leave the primary tumor site, invade surrounding tissue, and establish distant metastases. A hallmark of EMT is the loss of E-cadherin expression, and one major signal for the induction of EMT is TGFβ, which is dysregulated in up to 40% of hepatocellular carcinoma (HCC). We have constructed an EMT network of 70 nodes and 135 edges by integrating the signaling pathways involved in developmental EMT and known dysregulations in invasive HCC. We then used discrete dynamic modeling to understand the dynamics of the EMT network driven by TGFβ. Our network model recapitulates known dysregulations during the induction of EMT and predicts the activation of the Wnt and Sonic hedgehog (SHH) signaling pathways during this process. We show, across multiple murine (P2E and P2M) and human HCC cell lines (Huh7, PLC/PRF/5, HLE, and HLF), that the TGFβ signaling axis is a conserved driver of mesenchymal phenotype HCC and confirm that Wnt and SHH signaling are induced in these cell lines. Furthermore, we identify by network analysis eight regulatory feedback motifs that stabilize the EMT process and show that these motifs involve cross-talk among multiple major pathways. Our model will be useful in identifying potential therapeutic targets for the suppression of EMT, invasion, and metastasis in HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
19. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia.
- Author
-
Rajala, Hanna L. M., Eldfors, Samuli, Kuusanmäki, Heikki, van Adrichem, Arjan J., Olson, Thomas, Lagström, Sonja, Andersson, Emma I., Jerez, Andres, Clemente, Michael J., Yiyi Yan, Zhang, Dan, Awwad, Andy, Ellonen, Pekka, Kallioniemi, Olli, Wennerberg, Krister, Porkka, Kimmo, Maciejewski, Jaroslaw P., Loughran Jr, Thomas P., Heckman, Caroline, and Mustjoki, Satu
- Subjects
- *
LYMPHOCYTIC leukemia , *GENETIC mutation , *CYTOTOXIC T cells , *KILLER cells , *NUCLEOTIDE sequence , *GENETICS - Abstract
Large granular lymphocytic (LGL) leukemia is characterized by clonal expansion of cytotoxic T cells or natural killer cells. Recently, somatic mutations in the signal transducer and activator of transcription 3 (STAT3) gene were discove!ed in 28% to 40% of LGL leukemia patients. By exome and transcriptome sequencing of 2 STAT3 mutation-negative LGL leukemia patients, we identified a recurrent, somatic missense mutation (V665F) in the Src-like homology 2 domain of the STAT5b gene. Targeted amplicon sequencing of 211 LGL leukemia patients revealed 2 additional patients with STAT5b mutations (N642H), resulting in a total frequency of 2% (4 of 211) of STAT5b mutations across all patients. The Y665F and N642H mutant constructs increased the transcriptional activity of STAT5 and tyrosine (Y694) phosphorylation, which was also observed in patient samples. The clinical course of the disease in patients with the N642H mutation was aggressive and fatal, clearly different from typical LGL leukemia with a relatively favorable outcome. This is the first time somatic STAT5 mutations are discovered in human cancer and further emphasizes the role of STAT family genes in the pathogenesis of LGL leukemia. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
20. HTLV-2 Tax Immortalizes Human CD4+ Memory T Lymphocytes by Oncogenic Activation and Dysregulation of Autophagy.
- Author
-
Tong Ren, Wen Dong, Takahashi, Yoshinori, Di Xiang, Yunsheng Yuan, Xin Liu, Loughran Jr., Thomas P., Shao-Cong Sun, Hong-Gang Wang, and Hua Cheng
- Subjects
- *
T cells , *LEUKEMIA , *AUTOPHAGY , *PROTEINS , *MITOGENS - Abstract
Human T cell leukemia virus type 1 and type 2 (HTLV-1 and -2) are two closely related retroviruses with the former causing adult T cell leukemia. HTLV-2 infection is prevalent among intravenous drug users, and the viral genome encodes the viral transactivator Tax, which is highly homologous to the transforming protein Tax from HTLV-1. However, the link between HTLV-2 infection and leukemia has not been established. In the present study, we evaluated the activity of HTLV-2 Tax in promoting aberrant proliferation of human CD4 T lymphocytes. Tax2 efficiently immortalized CD4+ memory T lymphocytes with a CD3/TCRαβ/CD4/CD25/CD45RO/CD69 immunophenotype, promoted constitutive activation of PI3K/Akt, IκB kinase/NF-κB, mitogen-activated protein kinase, and STAT3, and it also increased the level of Mcl-1. Disruption of these oncogenic pathways led to growth retardation and apoptotic cell death of the Tax2-establishedTcell lines.Wefurther found that Tax2 induced autophagy by interacting with the autophagy molecule complex containing Beclin1 and PI3K class III to form the LC3+ autophagosome. Tax2-mediated autophagy promoted survival and proliferation of the immortalized T cells. The present study demonstrated the oncogenic properties of Tax2 in humanTcells and also implicated Tax2 in serving as a molecular tool to generate distinct T cell subtype lines. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
21. Discovery of Marinopyrrole A (Maritoclax) as a Selective Mcl-1 Antagonist that Overcomes ABT-737 Resistance by Binding to and Targeting Mcl-1 for Proteasomal Degradation.
- Author
-
Doi, Kenichiro, Rongshi Li, Shen-Shu Sung, Hongwei Wu, Yan Liu, Manieri, Wanda, Krishnegowda, Gowdahalli, Awwad, Andy, Dewey, Alden, Xin Liu, Amin, Shantu, Chunwei Cheng, Yong Qin, Schonbrunn, Ernst, Daughdrill, Gary, Loughran, Jr., Thomas P., Sebti, Said, and Hong-Gang Wang
- Subjects
- *
BCL-2 proteins , *APOPTOSIS , *CANCER treatment , *ANTINEOPLASTIC agents , *DRUG resistance in cancer cells - Abstract
The anti-apoptotic Bcl-2 family of proteins, including Bcl-2, Bcl-XL and Mcl-1, are well-validated drug targets for cancer treatment. Several small molecules have been designed to interfere with Bcl-2 and its fellow pro-survival family members. While ABT-737 and its orally active analog ABT-263 are the most potent and specific inhibitors to date that bind Bcl-2 and Bcl-XL with high affinity but have a much lower affinity for Mcl-1, they are not very effective as single agents in certain cancer types because of elevated levels of Mcl-1. Accordingly, compounds that specifically target Mcl-1 may overcome this resistance. In this study, we identified and characterized the natural product marinopyrrole A as a novel Mcl-1-specific inhibitor and named it maritoclax. We found that maritoclax binds to Mcl-1, but not Bcl-XL, and is able to disrupt the interaction between Bim and Mcl-1. Moreover, maritoclax induces Mcl-1 degradation via the proteasome system, which is associated with the pro-apoptotic activity of maritoclax. Importantly, maritoclax selectively kills Mcl-1-dependent, but not Bcl-2- or Bcl-XL-dependent, leukemia cells and markedly enhances the efficacy of ABT-737 against hematologic malignancies, including K562, Raji, and multidrugresistant HL60/VCR, by ∼60- to 2000-fold at 1-2 μM. Taken together, these results suggest that maritoclax represents a new class of Mcl-1 inhibitors, which antagonizes Mcl-1 and overcomes ABT-737 resistance by targeting Mcl-1 for degradation. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
22. Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia.
- Author
-
Clemente, Michael J., Wlodarski, Marcin W., Makishima, Hideki, Viny, Aaron D., Bretschneider, Isabell, Shaik, Mohammad, Bejanyan, Nelli, Lichtin, Alan E., His, Eric D., Paquette, Ronald L., Loughran Jr., Thomas P., and Maciejowski, Jaroslaw P.
- Subjects
- *
T cell receptors , *FLOW cytometry , *PEPTIDES , *MONOCLONAL antibodies , *LYMPHOCYTES - Abstract
T-cell large granular lymphocyte leukemia (T-LGLL) Is characterized by chronic lymphoproliferatlon of cytotoxic T lymphocytes (CTLs) and is associated with lineage-restricted cytopenias. irilroduction of T-cell receptor (TCR) variable β-chain (Vβ) monoclonal antibodies has facilitated identification and enumeration of clonal CTLs by flow cytometry. A highly skewed TCR V(t repertoire identified by flow cytometry is strongly associated With monoclonal CDR3 regions by quantitative sequencing and positive TCR-y rearrangement assays. Therefore, V13 expansions can serve as surrogate markers of CTL clonality to assess clonal kinetics In T-LGLL. We analyzed the TCR repertoire in 143 patients, 71 of which were available for serial measurements over 6 to 96 months. Although the majority (38/71, 54%) maintained a consistent monocional expansion, many (26/71, 37%) unexpectedly displayed a change In the dominant clone, whereby the original CTL clone contracted arid another emerged as demonstrated by V13 typing. Our results demonstrate that the 1-cell repertoire is more dynamic In T-LGLL than recognized previously, Illustrating the heterogeneity of disorders under this categorization. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
23. NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human.
- Author
-
Jianhua Yu, Mitsui, Takeki, Min Wei, Hsiaoyin Mao, Butchar, Jonathan P., Shah, Mithun Vinod, Jianying Zhang, Anjali Mishra, Alvarez-Breckenridge, Christopher, Xingluo Liu, Shujun Liu, Yokohama, Akihiko, Trotta, Rossana, Marcucci, Guido, Benson Jr., Don M., Loughran Jr., Thomas P., Tridandapani, Susheela, and Caligiuri, Michael A.
- Subjects
- *
LYMPHOCYTE transformation , *LEUKEMIA , *DISEASE susceptibility , *TRANSGENIC mice , *GROWTH factors , *T cells , *PATIENTS - Abstract
IL-15 may have a role in the development of T cell large granular lymphocyte (T-LGL) or NKT leukemias. However, the mechanisms of action and the identity of the cell subset that undergoes leukemic transformation remain elusive. Here we show that in both mice and humans, NKp46 expression marks a minute population of WT NKT cells with higher activity and potency to become leukemic. Virtually 100% of T-LGL leukemias in IL-15 transgenic mice expressed NKp46, as did a majority of human T-LGL leukemias. The minute NKp46- NKT population, but not the NKp46 NKT population, was selectively expanded by overexpression of endogenous IL-15. Importantly, IL-15 transgenic NKp46 NKT cells did not become NKp46+ in vivo, suggesting that NKp46+ T-LGL leukemia cells were the malignant counterpart of the minute WT NKp4+ NKT population. Mechanistically, NKp46+ NKT cells possessed higher responsiveness to IL-is in vitro and in vivo compared with that of their NKp46- NKT counterparts. Furthermore, interruption of IL-15 signaling using a neutralizing antibody could prevent LGL leukemia in IL-15 transgenic mice. Collectively, our data demonstrate that NKp46 identifies a functionally distinct NKT subset in mice and humans that appears to be directly susceptible to leukemic transformation when IL-15 is overexpressed. Thus, IL-15 signaling and NKp46 may be useful targets in the treatment of patients with T-LGL or NKT leukemia. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
24. Expansion of clonotypic T-cell populations in the peripheral blood of asymptomatic Gran Chaco...
- Author
-
Love, Jayne L., Marchioli, Carmine C., Dube, Syamalima, Bryz-Gornia, Virginia, Loughran Jr., Thomas P., Glaser, Jordan B., Esteban, Eduardo, Feldman, Leonardo, Ferrer, Jorge F., and Poiesz, Bernard J.
- Subjects
- *
HIV-positive persons , *INDIGENOUS peoples of the Americas , *DISEASES - Abstract
Analyzes peripheral blood mononuclear cells from asymptomatic human T-cell lymphotropic virus (HTLV)-II-infected and uninfected Gran Chaco Amerindians, using polymerase chain reaction (PCR) for expansion of clonotypic T-cell populations. Determination of HTLV infection; Reference to a link between HTLV-I with the adult T-cell lymphoma/leukemia.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.